Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective

Published:2022-05-25 Issue:6 Volume:22 Page:1033-1042
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

de Alava Enrique¹²^ORCID,Pareja María Jesús³⁴^ORCID,Carcedo David⁵^ORCID,Arrabal Natalia⁶,García José-Francisco⁶,Bernabé-Caro Reyes⁷^ORCID

Affiliation:

1. Pathology Unit, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain

2. Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain

3. Managing Director of the Health Management Area of South Sevilla, Spain

4. Coordinator of the Clinical Laboratory Network of Andalucia

5. Hygeia Consulting, Madrid, Spain

6. Roche Pharma SA, Madrid, Spain

7. Institute for Biomedical Research in Seville (IBIS/ SNRC/Seville University), Sevilla, Spain

Funder

Roche Farma S.A

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2078310

Reference35 articles.

1. Lung cancer: current therapies and new targeted treatments

2. Seom.org. [cited 2021 Dec 10]. Available from: https://seom.org/seomcms/images/stories/recursos/Cifras_del_cancer_2020.pdf

3. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

4. Precision Medicine in Non–Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review;Value in Health;2024-09

2. How is Value Defined in Molecular Testing in Cancer? A Scoping Review;Applied Health Economics and Health Policy;2024-07-09

3. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group;Annals of Oncology;2024-07

4. Cost analyses for malaria molecular diagnosis for research planners in India and beyond;Expert Review of Molecular Diagnostics;2024-05-20

5. Economic assessment of NGS testing workflow for NSCLC in a healthcare setting;Heliyon;2024-04